Newsroom

Sorted by: Latest

-

Mobileum lanza el paquete de conectividad GlobalRoamer® para la Copa Mundial de la FIFA 2026 con el fin de garantizar un roaming sin interrupciones y un rendimiento de voz 5G en toda Norteamérica

CUPERTINO, California--(BUSINESS WIRE)--Mobileum Inc. (“Mobileum”), proveedor líder mundial de soluciones analíticas y de red, anuncia un paquete Special GlobalRoamer® para la Copa Mundial de la FIFA 2026, diseñado para ayudar a las operadoras de redes móviles (MNO, por sus siglas en inglés) a validar la preparación para el roaming y mantener una conectividad de alta calidad durante uno de los eventos de red más exigentes del mundo, en el que el rendimiento del servicio repercute directamente e...
-

Agricultural Commodity Market Business Report 2025: Market to Reach $1.9 Trillion by 2030 - Increasing Investment in Agricultural Derivatives and Commodities Trading Platforms - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Agricultural Commodity Market - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Agricultural Commodity was valued at US$1.7 Trillion in 2024 and is projected to reach US$1.9 Trillion by 2030, growing at a CAGR of 2.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The global agricultu...
-

Corning Announces Outstanding 2025 Financial Results (1) – Upgrades Springboard Plan for Faster Sales Growth on Significantly Enhanced Financial Profile

CORNING, N.Y.--(BUSINESS WIRE)--Corning Incorporated (NYSE: GLW) today announced its fourth-quarter and full-year 2025 results and provided its outlook for first-quarter 2026. News Summary: Company delivers record results for Q4 and full-year 2025 and expects continued growth in Q1: Q4 core sales and core EPS grew 14% to $4.41 billion and 26% to $0.72, YoY, respectively. Full-year 2025 core sales grew 13% to $16.41 billion, and core EPS grew 29% to $2.52. In Q1, management expects YoY growth to...
-

Massachusetts Financial Services Company UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficia...
-

ACAMS Report Highlights Widening Gap Between Financial Criminals and AFC Professionals

WASHINGTON--(BUSINESS WIRE)--ACAMS, the global partner to the AML, fraud and sanctions communities, published its annual Global Anti-Financial Crime Threats Report identifying the top financial crime threats for the coming year. The report is based on a survey of 1,400 global AFC professionals across more than 200 jurisdictions. The report shows convergence of technology, geopolitics and criminal innovation is creating new threats of unprecedented scale and complexity. These threats are outpaci...
-

Shorla Oncology® Announces U.S. FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, in a larger vial size, 375mg/75mL, for adult and pediatric patients with T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL). Nelarabine Injection carries a Boxed Warning. Please see Important Safety Information below and full Pres...
-

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos’ 2025 NDA labeling supplement application, and re...
-

Melio Launches Agent Mel, an AI-Powered Assistant to Streamline Business Financial Decision-Making

NEW YORK--(BUSINESS WIRE)--Melio, a leading accounts payable and receivable platform, announced today the launch of “Agent Mel,” an AI-powered assistant and expert guide that delivers quick responses and valuable insight for payment, product, and vendor questions. The conversational agent helps accountants, bookkeepers, and SMBs access critical information and gain understanding to make faster, smarter decisions. As B2B sectors rapidly adopt AI, Agent Mel addresses the growing demand for intell...
-

Sokin Secures $100M in Growth Financing From Oxford Finance

LONDON--(BUSINESS WIRE)--Sokin, the global business payments company, has secured a $100 million long-term debt facility from Oxford Finance LLC (“Oxford”), a leading specialty lender. The facility will accelerate Sokin's expansion across North America, Asia, the Middle East, and South America, and fast-track the acquisition of further regional licenses, banking partnerships, and global infrastructure scaling. Additionally, investments will fund the development and launch of new products, inclu...
-

Aeva to Participate in the Oppenheimer 11th Annual Emerging Growth Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aeva® (Nasdaq: AEVA), a leader in next-generation sensing and perception systems, today announced that Aeva management will participate in the following investor event: Oppenheimer 11th Annual Emerging Growth Conference Location: Virtual Date: February 3, 2026 Institutional investors can contact their sales representative at Oppenheimer to register and request a meeting. About Aeva Technologies, Inc. (Nasdaq: AEVA) Aeva’s mission is to bring the next wave...